Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Columns

Q&A column

NOVEMBER 2024 Q. Our laboratory was cited for a deficiency because the manufacturer and methodology of our tumor marker assay was not available to clinicians. What is the reasoning behind this requirement? Read answer.
Q. For patients who have a hematocrit level greater than 55 percent, is it okay to use a CBC (hematocrit) that was not collected at the same time as the citrate sample? For example, can we use a CBC collected within 24 hours for an inpatient and a CBC from a previous visit for an outpatient? Read answer.

Newsbytes

November 2024—A picture may be worth a thousand words, but a conventional two-dimensional photograph of a surgical specimen can convey only so much information to a pathologist or surgeon. Overall geometry and margin status are difficult to interpret from static, single-perspective images.

Letters

November 2024—In “Lab test use: what 1 billion claims tell us” (August issue, page 1), you detailed the conclusions of a research study that analyzed insurance claims from effectively the entire U.S. adult population. The study found what it had sought, that 14.4 million individuals tested had undergone excessive laboratory testing, which is low-value care that poses patient risks and wastes resources. In reviewing the study data and analyses, I found that the methodology did not accurately estimate overuse and that the study overlooked the conclusion the data was screaming for: We are screening far too few people for chronic diseases and need to invest in access to care.

Put It on the Board

November 2024—The College of American Pathologists on Oct. 7 filed an amicus brief in support of the plaintiffs in the consolidated cases American Clinical Laboratory Association, et al., v. U.S. Food and Drug Administration, et al., and Association for Molecular Pathology, et al., v. U.S. Food and Drug Administration, et al. Plaintiffs in these consolidated cases challenge a final rule setting out the FDA’s plan to regulate LDTs as medical devices under the Federal Food, Drug and Cosmetic Act. “The Final Rule imposes draconian new restrictions—and crushing compliance costs—on the development and use of LDTs,” the CAP says in its amicus brief.

From the President’s Desk

October 2024—When this column comes out, many of us will be on our way to our annual meeting, held this year in Las Vegas. As I planned my presidential address for CAP24, I decided to focus on the future—the future of pathology and our future as pathologists. I’ll use this month’s column to cover the same theme. (And if some of you happen to read this column before I give my address, you will in a sense be seeing the future yourselves.)

Clinical pathology selected abstracts

October 2024—Exposure to lead is associated with irreversible adverse effects on fetal and neonatal development. Because no reliable threshold exists for determining the impact of lead exposure on children, the CDC began using the term blood lead reference values to identify children with higher blood lead levels (BLLs). Limiting exposure to lead is critical to ensuring that vulnerable populations, such as fetuses, neonates, and children, are not at risk for adverse neurodevelopmental outcomes. Lead and inorganic lead compounds are classified as carcinogens, while such metals as mercury and cadmium are considered neurotoxicants. Studies have shown a significant correlation between post-transfusion BLLs in infants and lead levels in RBC units.

Anatomic pathology selected abstracts

October 2024—Screening for colorectal cancers can involve assessing mismatch repair deficiency or microsatellite instability to identify people with Lynch syndrome, the most common hereditary syndrome causing colorectal cancer. Advanced adenomas are considered immediate precursor lesions of colorectal cancer. The authors conducted a study in which they investigated the relevance of microsatellite instability screening of advanced adenomas for Lynch syndrome in population screening. They selected advanced adenomas (n=1,572) from the Dutch colorectal cancer population screening program. All were reviewed and met one or more of the following criteria: tubulovillous (n=848, 54 percent) or villous (n=118, 7.5 percent) adenoma, diameter of 1 cm or more (n=1,286, 82 percent), or high-grade dysplasia (n=176, 11 percent).

Molecular pathology selected abstracts

October 2024—Huntington disease is a neurodegenerative disease caused by abnormal CAG trinucleotide repeats in exon one of the HTT gene, in which the number of CAG repeats affects disease presentation. Alleles with 40 or more CAG (cytosine, adenine, guanine) repeats are fully penetrant and age at disease onset is inversely correlated with number of repeats, while 36 to 39 CAG repeats are associated with reduced penetrance and fewer than 36 are not considered to cause Huntington disease. It is thought that inherited CAG repeats may undergo somatic expansion until a harmful threshold is reached before the degenerative process begins.

Pathology informatics selected abstracts

October 2024—The authors conducted a study to evaluate the Genius digital diagnostic system compared with manual light microscopy diagnosis using ThinPrep Pap test slides. Six cytologists and three cytopathologists participated in the study. They received 1.5 days of training on the Genius digital system from the manufacturer (Hologic, Marlborough, Mass.). They then analyzed 319 ThinPrep Pap test cases in the authors’ institutional cytology archive that represented a range of Bethesda System categories typically encountered in routine practice. The study participants assessed diagnostic accuracy by comparing digital and manual results to the original Pap test diagnosis, which was considered the reference diagnosis, or ground truth.

Newsbytes

October 2024—Conducting informal pathology clinics in his office to help patients better understand their diagnosis has been standard fare for John Groth, MD. But this will change in the coming months as he finishes setting up a formal clinic, replete with the technology and tools necessary to more easily educate patients at Endeavor Health’s Evanston Hospital.

MARKETPLACE

TRENDING